Wuhan Healthgen Biotechnology Management
Management criteria checks 3/4
Wuhan Healthgen Biotechnology's CEO is Daichang Yang, appointed in Jan 2024, has a tenure of 1.83 years. total yearly compensation is CN¥1.78M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 11.27% of the company’s shares, worth CN¥3.35B. The average tenure of the management team and the board of directors is 4.1 years and 1.8 years respectively.
Key information
Daichang Yang
Chief executive officer
CN¥1.8m
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 1.8yrs |
| CEO ownership | 11.3% |
| Management average tenure | 4.1yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -CN¥154m |
| Mar 31 2025 | n/a | n/a | -CN¥153m |
| Dec 31 2024 | CN¥2m | CN¥2m | -CN¥151m |
| Dec 31 2023 | CN¥2m | n/a | -CN¥187m |
Compensation vs Market: Daichang's total compensation ($USD250.81K) is about average for companies of similar size in the CN market ($USD200.52K).
Compensation vs Earnings: Daichang's compensation has been consistent with company performance over the past year.
CEO
Daichang Yang
Mr. Daichang Yang is Chairman & GM of Wuhan Healthgen Biotechnology Corp. from January 2024.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 1.8yrs | CN¥1.78m | 11.27% CN¥ 3.5b | |
| Chief Financial Officer | 13.1yrs | CN¥925.10k | 0.13% CN¥ 39.0m | |
| Chief Medical Officer | 4.7yrs | CN¥2.21m | no data | |
| Secretary of the Board | 3.5yrs | CN¥740.10k | no data | |
| Deputy General Manager | no data | CN¥827.70k | 0.16% CN¥ 50.5m | |
| Senior Director of Scientific Research Projects | no data | CN¥620.00k | 0.035% CN¥ 10.8m | |
| Director of Scientific Research Projects | no data | CN¥494.30k | 0.053% CN¥ 16.3m | |
| Senior Manager of Scientific Research Projects | no data | CN¥387.80k | 0.014% CN¥ 4.3m |
Experienced Management: 688765's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 1.8yrs | CN¥1.78m | 11.27% CN¥ 3.5b | |
| Director | 1.8yrs | no data | no data | |
| Supervisor | 1.8yrs | no data | no data | |
| Independent Director | 1.8yrs | CN¥102.00k | no data | |
| Director | 1.8yrs | no data | 0.38% CN¥ 116.1m | |
| Director | 1.8yrs | no data | no data | |
| Director | 1.8yrs | no data | 0.82% CN¥ 252.4m | |
| Director | 1.8yrs | CN¥513.50k | no data | |
| Chairman of the Board of Supervisors | 1.8yrs | no data | no data | |
| Independent Director | 1.8yrs | CN¥102.00k | no data | |
| Supervisor | 1.8yrs | no data | no data | |
| Independent Director | 1.8yrs | CN¥102.00k | no data |
Experienced Board: 688765's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 17:29 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wuhan Healthgen Biotechnology Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.